# Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

> **NCT02579616** · PHASE2 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 29 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT02579616
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-23
- **Primary completion:** 2016-11-22
- **Final completion:** 2019-02-27
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2020-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02579616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02579616, "Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02579616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*